Update for January 19, 2021
The FDA accepted the NDA for finerenone for the treatment of chronic kidney disease in patients with type 2 diabetes, suggesting a PDUFA date of 7/12/2021.
The FDA designated ligelizumab a Breakthrough Therapy for the treatment of chronic spontaneous urticaria in patients who have an inadequate response to H1-antihistamine treatment.
The FDA granted padeliporfin a Fast Track designation for the treatment of low-grade and unifocal high-grade Upper Tract Urothelial Cancer.
Announced Research Updates
Mesoblast announced that in the 30-month, 537 patient, Phase III, DREAM-HF trial, treatment with a single dose of rexlemestrocel-L resulted in a 20.6% incidence of cardiac death, heart attack or stroke compared to 30% incidence with placebo in patients with chronic heart failure with reduced left ventricular ejection fraction, that were receiving optimal oral therapy.
Published Research Updates
In a 162 patient, Phase II, open-label trial, treatment with olmutinib resulted in an objective response rate of 46.3% in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).
In the 96-week, 38 patient, Phase III, RESCUE trial, the eyes treated with lenadogen nolparvovec had an improvement in best corrected visual acuity of 10 letters on the ETDRS scale compared to a 9 letter gain in the eyes that received sham injection in patients with Leber Hereditary Optic Neuropathy.
In the 12-week, 88 patient, dose-ranging, Phase II STARS trial, 66.7% of patients treated with gaboxadol reduced their Clinical Global Impressions-Improvement scale (CGI-I) score compared to 39.3% with placebo in patients with Angelman syndrome. A post-hoc analysis examined the CGI-I score to determine the number of patients that were very much improved or much improved and found that 32.1% of patients that received gaboxadol once daily reached this threshold compared to 7.1% of placebo patients. There was not a significant improvement compared to placebo with gaboxadol twice daily.
In a 48-week, 75 patient, Phase II trial, patients treated with bimagrumab had a 20.5% decrease in total body fat mass compared to a 0.5% decrease with placebo in patients with obesity and type 2 diabetes.
In the 52-week, 1,252 patient, Phase III, FINCH 3 trial, the percentage of patients that achieved ACR20 at 24 weeks was 81% with filgotinib 200 mg plus methotrexate and 80% with filgotinib 100 mg plus methotrexate compared to 71% with methotrexate alone in patients with moderate-to-severe rheumatoid arthritis naive to methotrexate. There was no difference between the number of patients that achieved AR20 with filgotinib 200 mg alone compared to methotrexate alone.
Comments are closed.
Stay informed, subscribe to the
Prescribe Right Pharmaceutical Pipeline Tracker
Latest Tweets from Prescribe Right
© COPYRIGHT 2015. ALL RIGHTS RESERVED.